Psyence Biomedical LTD. (PBMWW) — SEC Filings

Overview

Psyence Biomedical LTD. (PBMWW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Nov 20, 2025: Psyence Biomedical Ltd. filed a Form 6-K on November 20, 2025, to report its unaudited interim consolidated financial statements for the three and six months ended September 30, 2025. The company is a foreign private issuer based in Toronto, Ontario, and files annual reports under Form 20-F.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 48 neutral. The dominant filing sentiment for Psyence Biomedical LTD. is neutral.

Filing Type Overview

Psyence Biomedical LTD. (PBMWW) has filed 38 6-K, 1 20-F/A, 3 20-F, 3 SC 13G, 4 SC 13G/A, 1 SC 13D with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

• 6-K Filing — 6-K · Nov 21, 2025
• Psyence Biomedical Ltd. Files Interim Financials — 6-K · Nov 20, 2025 Risk: low
  Psyence Biomedical Ltd. filed a Form 6-K on November 20, 2025, to report its unaudited interim consolidated financial statements for the three and six months en
• Psyence Biomedical Appoints CFO to Board, Amends Stock Purchase Agreement — 6-K · Nov 10, 2025 Risk: low
  Psyence Biomedical Ltd. announced the appointment of Warwick Corden-Lloyd, the company's Chief Financial Officer, to its Board of Directors, effective October 3
• Psyence Biomedical Ltd. Names New Head of Clinical Development — 6-K · Oct 9, 2025 Risk: low
  Psyence Biomedical Ltd. announced on October 9, 2025, that Dr. Neil Maresky has transitioned from CEO and Director to Global Head of Clinical Development. In hi
• Psyence Biomedical Buys PsyLabs Shares for $3.5M — 6-K · Sep 5, 2025 Risk: medium
  On August 15, 2025, Psyence Biomedical Ltd. entered into a subscription agreement with Psyence Labs Ltd. (PsyLabs). Under this agreement, PsyLabs will issue 1,7
• Psyence Biomedical Ltd. Files August 2025 Report (6-K) — 6-K · Aug 28, 2025 Risk: low
  Psyence Biomedical Ltd. filed a Form 6-K on August 28, 2025, reporting for the month of August 2025. The filing includes a press release as Exhibit 99.1. The co
• Psyence Biomedical Amends 20-F, Confirms Compliance & Share Count — 20-F/A · Jul 25, 2025 Risk: low
  PSYENCE BIOMEDICAL LTD. (PBMWW) filed an Amendment No. 1 to Form 20-F for the fiscal year ended March 31, 2025, indicating its status as an annual report. The c
• Psyence Biomedical Posts $10.5M Loss Amid Clinical Trial Push — 20-F · Jun 25, 2025 Risk: high
  PSYENCE BIOMEDICAL LTD. reported no revenue for the fiscal year ended March 31, 2025, consistent with its pre-commercialization stage. The company incurred a ne
• Psyence Biomedical Ltd. Enters LOI with Southern Star Research — 6-K · Jun 11, 2025 Risk: low
  On April 2, 2025, Psyence Biomedical Ltd. announced a binding letter of intent (LOI) with Southern Star Research Pty Ltd, an Australian contract research organi
• Psyence Biomedical Ltd. Files 6-K Report — 6-K · May 20, 2025 Risk: low
  Psyence Biomedical Ltd. filed a Form 6-K on May 20, 2025, reporting its status as a foreign private issuer. The company, located at 121 Richmond Street West, Pe
• Psyence Biomedical Ltd. Files Form 6-K — 6-K · May 6, 2025 Risk: low
  Psyence Biomedical Ltd. filed a Form 6-K on May 6, 2025, reporting information for the month of May 2025. The filing includes a press release as Exhibit 99.1. T
• Psyence Biomedical Ltd. Approves Up to 50-for-1 Reverse Stock Split — 6-K · Apr 23, 2025 Risk: medium
  Psyence Biomedical Ltd. held a Special Meeting of Shareholders on April 16, 2025, to approve a share consolidation proposal. The board of directors is authorize
• Psyence Biomedical Ltd. to Conduct Phase IIb Trial for Alcohol Use Disorder — 6-K · Apr 11, 2025 Risk: medium
  On April 2, 2025, Psyence Biomedical Ltd. announced a binding letter of intent (LOI) with Southern Star Research Pty Ltd for Psyence Australia Pty Ltd to conduc
• Psyence Biomedical Ltd. Files 6-K, Incorporates Corporate Update — 6-K · Apr 1, 2025 Risk: low
  Psyence Biomedical Ltd. filed a Form 6-K on April 1, 2025, to incorporate by reference a Corporate Update (Exhibit 99.1) into its existing Registration Statemen
• Psyence Biomedical Ltd. Calls Special Shareholder Meeting — 6-K · Mar 31, 2025 Risk: low
  Psyence Biomedical Ltd. filed a Form 6-K on March 31, 2025, announcing a Special Meeting of Shareholders scheduled for April 16, 2025. The filing includes the n
• Psyence Biomedical Ltd. Files 6-K with Financial Instrument Details — 6-K · Jan 23, 2025 Risk: medium
  Psyence Biomedical Ltd. filed a 6-K report for the period ending September 30, 2024. The filing includes details on various financial instruments such as warran
• Psyence Biomedical Files 6-K Detailing Securities Agreements — 6-K · Dec 31, 2024 Risk: medium
  Psyence Biomedical Ltd. filed a Form 6-K on December 31, 2024, reporting on events for the month of December 2024. The filing includes several exhibits related
• Psyence Biomedical Ltd. Files 6-K Report — 6-K · Dec 23, 2024 Risk: low
  Psyence Biomedical Ltd. filed a Form 6-K on December 23, 2024, reporting for the month of December 2024. The filing includes a press release as Exhibit 99.1. Dr
• Psyence Biomedical Ltd. inks deals with Optimi Health Corp. — 6-K · Dec 19, 2024 Risk: medium
  On December 5, 2024, Psyence Biomedical Ltd. entered into three definitive agreements with Optimi Health Corp. These agreements include an Intellectual Property
• Psyence Biomedical Ltd. Files 6-K Report — 6-K · Dec 18, 2024 Risk: low
  Psyence Biomedical Ltd. filed a Form 6-K on December 18, 2024, reporting information for the month of December 2024. The filing includes a press release as Exhi
• SC 13G Filing — SC 13G · Dec 13, 2024
• SC 13G/A Filing — SC 13G/A · Dec 9, 2024
• SC 13G/A Filing — SC 13G/A · Dec 4, 2024
• Psyence Biomedical Ltd. Files 6-K on Debt-for-Equity Swap — 6-K · Dec 4, 2024 Risk: medium
  Psyence Biomedical Ltd. filed a Form 6-K on December 4, 2024, reporting on a Debt-for-Equity Swap Agreement effective September 30, 2024, and a First Addendum t
• Psyence Biomedical Ltd. Files Form 6-K — 6-K · Dec 3, 2024 Risk: low
  Psyence Biomedical Ltd. filed a Form 6-K on December 3, 2024, to report a press release. The filing includes the signature of Dr. Neil Maresky, Chief Executive
• Psyence Biomedical Ltd. Files 6-K with Key Agreements and Nasdaq News — 6-K · Nov 22, 2024 Risk: medium
  Psyence Biomedical Ltd. filed a Form 6-K on November 22, 2024, reporting on several key events. These include a Termination Agreement dated November 21, 2024, a
• SC 13G/A Filing — SC 13G/A · Nov 13, 2024
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• Psyence Biomedical Ltd. Files 6-K Report — 6-K · Nov 12, 2024 Risk: low
  Psyence Biomedical Ltd. filed a Form 6-K on November 12, 2024, reporting for the month of November 2024. The filing includes a press release as Exhibit 99.1. Th
• SC 13G Filing — SC 13G · Nov 12, 2024
• Psyence Biomedical Ltd. Files 6-K Report — 6-K · Nov 1, 2024 Risk: low
  Psyence Biomedical Ltd. filed a Form 6-K on November 1, 2024, reporting for the month of November 2024. The filing includes a press release as Exhibit 99.1. Dr.
• Psyence Biomedical Schedules Shareholder Meeting, Files Financials — 6-K · Oct 23, 2024 Risk: low
  Psyence Biomedical Ltd. has filed a Form 6-K, announcing its Annual General and Special Meeting of Shareholders scheduled for November 12, 2024. The filing also
• Psyence Biomedical Swaps Debt for Equity — 6-K · Oct 8, 2024 Risk: medium
  Psyence Biomedical Ltd. announced on September 30, 2024, that it entered into debt-for-equity swap agreements. This move aims to restructure the company's debt
• Psyence Biomedical Ltd. Enters Share Purchase Agreement — 6-K · Sep 20, 2024 Risk: medium
  On September 17, 2024, Psyence Biomedical Ltd. entered into a Share Purchase and Sale Agreement. The filing does not specify the other party involved or the fin
• Psyence Biomedical Ltd. Issues Press Release — 6-K · Sep 13, 2024 Risk: low
  On September 13, 2024, Psyence Biomedical Ltd. announced the issuance of a press release. The company, incorporated in Ontario, Canada, is a pharmaceutical prep
• Psyence Biomedical Ltd. Enters New License Agreement — 6-K · Sep 5, 2024 Risk: medium
  On September 3, 2024, Psyence Biomedical Ltd. entered into a license agreement concerning alcohol and substance use disorders. The filing does not specify the o
• Psyence Biomedical Ltd. Files Investor Presentation 6-K — 6-K · Aug 30, 2024 Risk: low
  Psyence Biomedical Ltd. filed a Form 6-K on August 30, 2024, to report an investor presentation. This presentation is intended for use by management in discussi
• Psyence Biomedical Ltd. Enters Securities Agreement Addendum — 6-K · Aug 20, 2024 Risk: low
  On August 15, 2024, Psyence Biomedical Ltd. entered into a first addendum to a Securities Purchase Agreement. The filing is a Form 6-K, reporting for the month
• Psyence Biomedical Ltd. Enters Stock Purchase Agreement — 6-K · Jul 31, 2024 Risk: medium
  On July 25, 2024, Psyence Biomedical Ltd. entered into a Common Stock Purchase Agreement. The filing does not specify the other party or the financial terms of
• Psyence Biomedical Ltd. Files 20-F Report — 20-F · Jul 29, 2024 Risk: medium
  Psyence Biomedical Ltd. filed its 20-F report for the period ending March 31, 2024. The company, incorporated in A6 and headquartered in Toronto, operates in th
• Psyence Biomedical Ltd. Files 6-K on Agreement Changes — 6-K · Jul 24, 2024 Risk: low
  Psyence Biomedical Ltd. filed a Form 6-K on July 24, 2024, reporting on the modification and termination of material agreements involving Psyence Group Inc. (PG
• Psyence Biomedical Ltd. Files 6-K Update — 6-K · Jul 23, 2024 Risk: low
  Psyence Biomedical Ltd. filed a Form 6-K on July 23, 2024, providing an update related to its initial business combination that closed on January 15, 2024. The
• Psyence Biomedical Faces Nasdaq Delisting Risk — 6-K · Jul 5, 2024 Risk: medium
  On June 27, 2024, Psyence Biomedical Ltd. received a notification letter from Nasdaq regarding its failure to meet the minimum bid price requirement, with a com
• Psyence Biomedical Ltd. Files 6-K Update — 6-K · Jun 20, 2024 Risk: low
  Psyence Biomedical Ltd. filed a Form 6-K on June 20, 2024, providing an update as a foreign private issuer. The filing references a previous disclosure from Jan
• Psyence Biomedical Ltd. Files 6-K Update — 6-K · Jun 6, 2024 Risk: low
  Psyence Biomedical Ltd. filed a Form 6-K on June 6, 2024, providing an update on its business. The filing references a previous disclosure from January 15, 2024
• Psyence Biomedical Ltd. Files Form 6-K — 6-K · Mar 15, 2024 Risk: low
  On March 15, 2024, Psyence Biomedical Ltd. announced the issuance of a press release. The company, incorporated in Ontario, Canada, is a pharmaceutical preparat
• Psyence Biomedical Ltd. Files Form 6-K for March 2024 — 6-K · Mar 12, 2024 Risk: low
  On March 6, 2024, Psyence Biomedical Ltd. announced the issuance of a press release. The company, incorporated in Ontario, Canada, is a pharmaceutical preparati
• Harraden Circle Investments Takes 9.99% Stake in Psyence Biomedical — SC 13G · Feb 5, 2024
  Harraden Circle Investments, LLC, a New York-based investment firm, reported on February 5, 2024, that it beneficially owns 9.99% of Psyence Biomedical Ltd. (NA
• Psyence Group Inc. Discloses Significant Stake in Psyence Biomedical — SC 13D · Feb 5, 2024
  Psyence Group Inc. filed an SC 13D on February 5, 2024, disclosing its ownership of Common Shares in Psyence Biomedical Ltd. This filing indicates that Psyence
• Psyence Biomedical Ltd. Files Annual Report on Form 20-F — 20-F · Jan 31, 2024 Risk: low
  PSYENCE BIOMEDICAL LTD. (PBMWW) filed a Foreign Annual Report (20-F) with the SEC on January 31, 2024. Psyence Biomedical Ltd. filed a Form 20-F on January 31,

Risk Profile

Risk Assessment: Of PBMWW's 41 recent filings, 1 were flagged as high-risk, 14 as medium-risk, and 26 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• Warwick Corden-Lloyd
• Dr. Neil Maresky
• Neil Maresky

Industry Context

Psyence Biomedical Ltd. operates within the pharmaceutical preparations industry, a sector characterized by extensive research and development, stringent regulatory oversight, and significant capital requirements. The industry is competitive, with companies focusing on drug discovery, development, and commercialization, often involving specialized therapeutic areas. Trends include advancements in biotechnology, personalized medicine, and the increasing role of specialized treatments.

Top Tags

filing (7) · sec-filing (7) · foreign-private-issuer (5) · corporate-update (5) · reporting (5) · regulatory-filing (4) · corporate-action (4) · pharmaceuticals (4) · material-agreement (3) · partnership (3)

Key Numbers

• Transaction Value: $3.5M — Total amount Psyence Biomedical Ltd. is investing in Psyence Labs Ltd.
• Shares Acquired: 1,750 — Number of shares of Psyence Labs Ltd. purchased by Psyence Biomedical Ltd.
• Price Per Share: $2,000 — The cost for each share of Psyence Labs Ltd.
• Common shares outstanding: 568,021 — As of March 31, 2025, indicating the company's equity structure.
• Warrant exercise price: $6,874.13 — Per share for PBMWW warrants, relevant for potential dilution and valuation.
• Fiscal year end: March 31, 2025 — The period covered by the annual report.
• Months of required filings: 12 — Company has filed all reports for the preceding 12 months.
• Days subject to filing requirements: 90 — Company has been subject to filing requirements for the past 90 days.
• Net Loss: $10.5M — For the fiscal year ended March 31, 2025, indicating significant operational expenses without revenue.
• Revenue: 0 — For the fiscal year ended March 31, 2025, highlighting its pre-commercialization stage.
• Common Shares Outstanding: 568,021 — As of March 31, 2025, indicating the current share count.
• Warrant Exercise Price: $6,874.13 — Per share for PBMWW warrants, a high exercise price.
• Share Consolidation Ratio: 50-for-1 — Maximum ratio authorized for reverse stock split
• Total Assets: $130.7M — As of March 31, 2024, indicating the company's resources.
• Total Liabilities: $12.5M — As of March 31, 2024, representing the company's obligations.

Related Companies

PBM · PSYG

Frequently Asked Questions